HPRA Drug Safety Newsletter Edition 92
Download:
hpra-drug-safety-newsletter-edition-92.pdf
272 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates regarding the following medicines:
- Use of Lemtrada restricted while EMA review is on-going
- SGLT-2 inhibitors and risk of Fourniers Gangrene
- Cobicistat boosted darunavir and elvitegravir – avoid use in pregnancy due to potential risk of virological failure in second and third trimester
- Direct-Acting Antivirals for chronic hepatitis C – Risk of hypoglycaemia in patients with diabetes
- Biotin – Interference with clinical laboratory tests
« Back